Marker Therapeutics, Inc. (MRKR): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

Older than the company's other figures. The latest EBITDA is for the year ended 2022-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$17.00M
Year ended 2022-12-31
2019-12-31: -$22.42M2020-12-31: -$28.40M2021-12-31: -$37.33M2022-12-31: -$17.00M-$17.00M
2019-12-31 EBITDA (USD) 2022-12-31
Period endedEBITDAChange YoYSource filing
2022-12-31-$17.00Mn/c2024-03-26, From 2022-01-01
2021-12-31-$37.33Mn/m2023-03-22, From 2021-01-01
2020-12-31-$28.40Mn/m2022-03-17, From 2020-01-01
2019-12-31-$22.42Mn/a2021-03-09, From 2019-01-01